恩替卡韦联合聚乙二醇干扰素或胸腺素治疗代偿期乙型肝炎肝硬化2年疗效随访*

doi:10.3969/j.issn.1672-5069.2019.01.025

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (1): 93-96.doi: 10.3969/j.issn.1672-5069.2019.01.025

恩替卡韦联合聚乙二醇干扰素或胸腺素治疗代偿期乙型肝炎肝硬化2年疗效随访^*

曹艳平, 隋洪婷, 潘猛, 曲宝聚, 朴红心

133000 吉林省延吉市延边大学（曹艳平,隋洪婷,潘猛）; 附属医院感染病科（曲宝聚,朴红心）

收稿日期:2018-01-19 出版日期:2019-01-10 发布日期:2019-01-16
通讯作者: 朴红心,E-mail:15526770394@163.com
作者简介:曹艳平,女,硕士研究生。E-mail:569905136@qq.com
基金资助:
*国家科技重大专项973课题（编号：2017ZX10203202-003-006）

Efficacy of entecavir and peg-IFNα-2a or thymosin α1 combination in the treatment of patient with compensated hepatitis B liver cirrhosis

Cao Yanping, Sui Hongting, Pan Meng, et al.

Department of Infectious Diseases,Affiliated Hospital,Yanbian University,Yanji 133000,Jilin Province,China

Received:2018-01-19 Online:2019-01-10 Published:2019-01-16

摘要/Abstract

摘要： 目的探讨应用恩替卡韦联合聚乙二醇干扰素α-2a（PEG-IFNα-2a）或胸腺素治疗代偿期乙型肝炎肝硬化患者的效果。方法在88例代偿期乙型肝炎肝硬化患者中,接受恩替卡韦治疗者38例,接受恩替卡韦联合PEG-IFNα-2a治疗者17例,联合胸腺素治疗者33例,随访2年。结果恩替卡韦治疗组治疗前和治疗104 w末血清HBV DNA水平分别为（5.6±1.7） IU/ml和（1.0±0.7） IU/ml（P<0.05）,联合PEG-IFNα-2a组分别为（5.8±1.3） IU/ml和（1.0±0.7） IU/ml（P<0.05）,联合胸腺素组分别为（6.1±2.0） IU/ml和（1.0±0.9） IU/ml（P<0.05）;恩替卡韦组治疗前和治疗104 w末血清ALB水平分别为（43.1±5.4） g/L和（46.9±4.9） g/L（P<0.05）,联合胸腺素组分别为（43.0±4.0） g/L和（46.8±5.4） g/L（P<0.05）;三组治疗前和治疗104 w末肝脏硬度值和INR无统计学差异（P>0.05）。结论恩替卡韦能有效抑制HBV DNA复制,维持代偿期肝硬化患者的肝功能,本研究结果看不出联合用药有任何好处,需要进一步观察。

关键词: 肝硬化, 乙型肝炎, 恩替卡韦, 聚乙二醇干扰素, 胸腺素, 疗效

Abstract: Objective To evaluate the efficacy of entecavir and peg-IFNα-2a or thymosin α1 combination in the treatment of patient with compensated hepatitis B liver cirrhosis. Methods In this study,88 patients with compensated hepatitis B cirrhosis were selected,and 38 received entecavir, 17 received entecavir combined with PEG-IFNα-2a and 33 received entecavir and thymosin α1 combination for 104 weeks. Results Serum HBV DNA levels in the entecavir monotherapy group before treatment and at the end of 104 week were （5.6±1.7） IU/ml and （1.0±0.7） IU/ml,respectively （P<0.05）,in PEG-IFNα-2a combination group were （5.8±1.3） IU/ml and （1.0±0.7） IU/ml,respectively（P<0.05） and in combined with thymosin group were （6.1±2.0） IU/ml and（1.0±0.9） IU/ml, respectively（P<0.05）;serum albumin levels in the entecavir group before treatment and at the end of 104 week were （43.1±5.4） g/L and （46.9±4.9） g/L,respectively （P<0.05）,and in combined thymosin group were （43.0±4.0） g/L and（46.8±5.4）g/L,respectively（P<0.05）;there were no significant differences as respect to liver stiffness measures and INRs among the three groups （P>0.05）. Conclusion Entecavir monotherapy could effectively inhibit the replication of HBV DNA, and improve liver function tests and we don’t find any advantages of combination with PEG-IFNα-2a or thymosin-α1 from the results of this study.

Key words: Liver cirrhosis, Hepatitis B, Entecavir, Peg-IFNα-2a, Thymosin-α1, Therapy

曹艳平, 隋洪婷, 潘猛, 曲宝聚, 朴红心. 恩替卡韦联合聚乙二醇干扰素或胸腺素治疗代偿期乙型肝炎肝硬化2年疗效随访^*[J]. 实用肝脏病杂志, 2019, 22(1): 93-96.

Cao Yanping, Sui Hongting, Pan Meng, et al.. Efficacy of entecavir and peg-IFNα-2a or thymosin α1 combination in the treatment of patient with compensated hepatitis B liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 93-96.

参考文献

[1] World Health Organization.Health in 2015:From MDGs to SDGs;World Health Organization:Genova,Switherland,2015.
[2] Zampino R,Boemio A,Sagnelli C,et al.Hepatitis B virus burden in developing countries. World J Gastroenterol,2015,21(42):11941-11953.
[3] Zuo C,Xia M,Wu Q,et al.Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection. Oncol Lett,2015,9(2):527-534.
[4] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[5] Sandhu P,Haque M,Humphries-Bickley T,et al. Hepatitis B virus immunopathology,model systems,and current therapies. Front Immunol,2017,13,8:436.
[6] Kubo S,Takemura S,Tanaka S,et al.Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol,2015,21(27):8249-8255.
[7] Kim JH,Sinn DH,Kim K,et al.Lamivudine versus entecavir for newly diagnosed hepatitis B virus-related hepatocellular carcinoma. Gut Liver,2016,10(6):939-947.
[8] Romani L,Oikonomou V,Moretti S,et al.Thymosinα1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nat Med,2017,23(5):590-600.
[9] 尤红,吴晓宁,贾继东,等. 恩替卡韦对慢性乙型肝炎、肝硬化代偿期和失代偿期的2年抗病毒疗效比较. 首都医科大学学报,2010,31(5):563-565.
[10] 张洪玲,权海燕,林梅花,等. 国产恩替卡韦治疗乙型肝炎肝硬化患者52周疗效分析. 实用肝脏病杂志,2016,19(6):726-727.
[11] 刁云辉,薛萌,樊宏伟,等. 胸腺肽α1注射剂联合恩替卡韦胶囊治疗肝硬化肝功能代偿期的临床研究. 中国临床药理学杂志,2017,33(11):974-976.
[12] Xu Y,Wu XN,Shi YW,et al.Baseline hepatitis B virus DNA level is a promising factor for predicting the 3(rd) month virological response to entecavir therapy:a study of strict defined hepatitis B virus induced cirrhosis. Chin Med J,2015,128(14):1867-1872.
[13] Naylor PH,Mutchnick MG.Immunotherapy for hepatitis B in the direct acting antiviral era:reevaluating the thymosinα1 efficacy trials in the light of a combination therapy approach. J Viral Hepat,2018,25(1):4-9.
[14] Okada M,Enomoto M,Kawada N.Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol,2017,11(12):1095-1104.
[15] Tai CT,Kao JH.Elimination of hepatitis B:is it a mission possible. BMC Med,2017,15:53.
[16] Arends JE,Faydra I,Lieveld,et al. New viral and immunological targets for hepatitis B treatment and cure:a review. Infect Dis Ther,2017,6(4):461-476.
[17] Cantin AM,Hanrahan JW.Thymosinα1:asingle drug with multiple targets in cystic fibrosis. Nat Med,2017,23(5):536-538.
[18] King R,Tuthill C.Immune modulation with thymosin alpha 1 treatment. Vitam Horm,2016,102:151-178.
[19] Guo H,Jiang D,Zhou T,et al.Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus:an intermediate of covalently closed circular DNA formation. J Virol,2007,81(22):12472-12484.
[20] Liu Y,Li J,Chen J,et al.Hepatitis B virus polymerase disrupts K63-linked ubiquitination of sting to block innate cytosolic DNA-sensing pathways. J Virol,2015,89(4):2287-2300.

恩替卡韦联合聚乙二醇干扰素或胸腺素治疗代偿期乙型肝炎肝硬化2年疗效随访^*

Efficacy of entecavir and peg-IFNα-2a or thymosin α1 combination in the treatment of patient with compensated hepatitis B liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[8]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[9]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[10]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[11]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[12]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[13]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[14]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[15]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.